RhumbLine Advisers’s ADMA Biologics ADMA Stock Holding History

RhumbLine Advisers’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.49M	Sell	535,862 -92,083	-15%	-$839K	﹤0.01%	1531
2026 Q1	$5.66M	Buy	627,945 +14,645	+2%	+$231K	﹤0.01%	1341
2025 Q4	$11.2M	Sell	613,300 -37,320	-6%	-$629K	0.01%	1008
2025 Q3	$9.54M	Sell	650,620 -1,938	-0.3%	-$33.2K	0.01%	1100
2025 Q2	$11.9M	Buy	652,558 +30,391	+5%	+$620K	0.01%	983
2025 Q1	$12.3M	Buy	622,167 +1,088	+0.2%	+$18.8K	0.01%	926
2024 Q4	$10.7M	Buy	621,079 +5,881	+1%	+$111K	0.01%	1021
2024 Q3	$12.3M	Buy	615,198 +304,659	+98%	+$4.74M	0.01%	964
2024 Q2	$3.47M	Buy	310,539 +15,844	+5%	+$133K	﹤0.01%	1597
2024 Q1	$1.94M	Buy	294,695 +6,348	+2%	+$34.7K	﹤0.01%	1921
2023 Q4	$1.3M	Buy	288,347 +617	+0.2%	+$2.28K	﹤0.01%	2126
2023 Q3	$1.03M	Buy	287,730 +8,106	+3%	+$31.2K	﹤0.01%	2192
2023 Q2	$1.03M	Sell	279,624 -3,747	-1%	-$13.9K	﹤0.01%	2267
2023 Q1	$938K	Buy	283,371 +33,776	+14%	+$117K	﹤0.01%	2155
2022 Q4	$968K	Buy	249,595 +3,002	+1%	+$9.26K	﹤0.01%	2146
2022 Q3	$599K	Buy	246,593 +15,479	+7%	+$37.1K	﹤0.01%	2412
2022 Q2	$458K	Buy	+231,114	New	+$455K	﹤0.01%	2537
2021 Q2	–	Sell	-64,698	Closed	-$114K	–	2983
2021 Q1	$114K	Buy	64,698 +100	+0.2%	+$229	﹤0.01%	2921
2020 Q4	$126K	Buy	64,598 +6,028	+10%	+$12.7K	﹤0.01%	2938
2020 Q3	$140K	Sell	58,570 -10,804	-16%	-$29.6K	﹤0.01%	2792
2020 Q2	$203K	Buy	69,374 +20,601	+42%	+$59.2K	﹤0.01%	2765
2020 Q1	$140K	Buy	48,773 +2,409	+5%	+$8.33K	﹤0.01%	2698
2019 Q4	$185K	Buy	46,364 +523	+1%	+$2.28K	﹤0.01%	2772
2019 Q3	$204K	Buy	45,841 +16,443	+56%	+$68.7K	﹤0.01%	2741
2019 Q2	$114K	Buy	29,398 +6,599	+29%	+$29.1K	﹤0.01%	2907
2019 Q1	$86K	Sell	22,799 -480	-2%	-$1.7K	﹤0.01%	2879
2018 Q4	$56K	Buy	23,279 +7,810	+50%	+$38.7K	﹤0.01%	2935
2018 Q3	$96K	Sell	15,469 -591	-4%	-$3.4K	﹤0.01%	2873
2018 Q2	$72K	Buy	+16,060	New	+$80K	﹤0.01%	2893

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RhumbLine Advisers's ADMA Position: Q2 2026 in Review

RhumbLine Advisers reduced its ADMA Biologics (ADMA) stake by 15% in Q2 2026, selling an estimated $839K and leaving 535,862 shares worth $4.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1531.

RhumbLine Advisers first reported a position in ADMA in Q2 2018 and has held it in 29 quarters since. The position peaked at $12.3M in Q1 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

RhumbLine Advisers held 535,862 shares of ADMA Biologics worth $4.49M as of Q2 2026.
RhumbLine Advisers sold 92,083 ADMA Biologics shares in Q2 2026, an estimated $839K.
ADMA Biologics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1531 holding.
RhumbLine Advisers first reported a position in ADMA Biologics in Q2 2018 and has held it in 29 quarters since.
RhumbLine Advisers's ADMA Biologics position peaked at $12.3M in Q1 2025.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.